Aberrant expression and reverse signalling of CD70 on malignant B cells.
about
CD70/CD27 ligand, a member of the TNF family, is expressed in human brain tumorsCD70+ non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD4+CD25 T cellsMultiple interactions of the cytosolic polyproline region of the CD95 ligand: hints for the reverse signal transduction capacity of a death factorIdentification of interaction partners of the cytosolic polyproline region of CD95 ligand (CD178)Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma.Enhancement of adenovirus vector entry into CD70-positive B-cell Lines by using a bispecific CD70-adenovirus fiber antibodyTargeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody-drug conjugate SGN-75Exome sequencing reveals novel mutation targets in diffuse large B-cell lymphomas derived from Chinese patients.T cells redirected against CD70 for the immunotherapy of CD70-positive malignanciesExpression of the immune regulation antigen CD70 in osteosarcoma.Pancreatic ductal adenocarcinoma: a review of immunologic aspects.Immunotherapy targets in pediatric cancer.CD70 expression patterns in renal cell carcinoma.Immunotherapy in allogeneic hematopoietic stem cell transplantation--not just a case for effector cells.Markers of B-cell activation in relation to risk of non-Hodgkin lymphoma.CD70 as a therapeutic target in human malignancies.CD70 is downregulated by interaction with CD27.Secreted primary human malignant mesothelioma exosome signature reflects oncogenic cargo.Investigational antibody-drug conjugates for hematological malignancies.Antibody-drug conjugates for the treatment of B-cell non-Hodgkin's lymphoma and leukemia.Expression of CD70 (CD27L) Is Associated With Epithelioid and Sarcomatous Features in IDH-Wild-Type Glioblastoma.Therapeutic targeting of CD70 and CD27.Expression of CD70 in nasal natural killer/T cell lymphoma cell lines and patients; its role for cell proliferation through binding to soluble CD27.Signalling via CD70, a member of the TNF family, regulates T cell functions.Targeted alpha therapy using a novel CD70 targeted thorium-227 conjugate in in vitro and in vivo models of renal cell carcinoma.Protein profiling of plasma membranes defines aberrant signaling pathways in mantle cell lymphoma.Chronic lymphocytic leukemia cells display p53-dependent drug-induced Puma upregulation.Pharmacokinetic characterization of BMS-936561, an anti-CD70 antibody-drug conjugate, in preclinical animal species and prediction of its pharmacokinetics in humans.Application of chimeric antigen receptor-engineered T cells in ovarian cancer therapy.The costimulatory molecule CD70 is regulated by distinct molecular mechanisms and is associated with overall survival in diffuse large B-cell lymphoma.Soluble CD27 induces IgG production through activation of antigen-primed B cells.Investigatory and analytical approaches to differential gene expression profiling in mantle cell lymphoma.Mechanisms of Immune Evasion and Immune Modulation by Lymphoma Cells.CD40 stimulation of B-cell chronic lymphocytic leukaemia cells enhances the anti-apoptotic profile, but also Bid expression and cells remain susceptible to autologous cytotoxic T-lymphocyte attack.Hypoxia-inducible factor-2 alpha up-regulates CD70 under hypoxia and enhances anchorage-independent growth and aggressiveness in cancer cells.
P2860
Q24292789-56114A97-58C8-406C-A66F-D7943E55D1A5Q24681974-4AAC7F66-D1A1-4AE4-95B7-DFA7C3C0E10CQ28210406-FCE6CB9B-C0C2-47B7-BEE7-43C647C96954Q28218575-2CCEEE1F-35B9-4DC6-8B67-2D67EF91473CQ33417191-223533DF-1436-45B6-935C-7DFC29314C03Q33851887-5AFC6543-823C-4A82-8ABD-480146040FA7Q34122802-068269CF-FBFA-42CC-8964-7F4B94F2D2B0Q34353717-89A0302E-AA1F-44DC-9E3E-C70C89CD5EDFQ34923799-3FD20C2C-CD85-4DC5-9C34-D586468A15E9Q35194116-4953963E-ACAD-48CD-A747-5C2FB025EF9BQ35870682-6E32DE6B-653A-4F7F-8C5F-59201FB8712EQ35971029-E006BE57-77D8-457A-8F20-C91739DA463BQ36028302-9922C29B-835C-47EE-8C31-88CAE17479CBQ36090223-A7991342-473D-4558-A5DD-0564F90DB106Q36243608-550D4745-4742-4437-8C01-B63AE58B4D1CQ37082785-34FFAB2F-2434-4ECA-86FA-103AC93E5196Q37112436-5E6F4922-7131-416E-9DE0-C2C5EA7EA824Q37240065-0464367A-CF94-4D9C-A009-56045491B413Q37818256-1C78A895-1D5C-4D5A-9303-84FFD31673EEQ38087390-AC6A8062-1E3A-448B-84F4-4B75D6359311Q38633640-0795F6C4-3A08-45FC-8BCF-C4E3276859C5Q38749841-22549F07-A30E-47E3-8EB5-94889B3E3A9AQ39233648-477DDA69-C8B9-451A-9BD8-8FC2955D4FADQ40540340-C1966659-2859-4D33-9846-E999C582624DQ41346916-4AA860CF-313D-4EAB-B5CF-907F583D8ABCQ41971312-B95FE28C-6B44-4B33-8858-FD00692082E4Q45240553-A7504322-573F-4863-9FD6-911564D88754Q46203720-184B732E-6755-4A33-B8E9-4BCDCB97173FQ50027358-A20F7472-5D59-4D58-95D6-D9BAAE943832Q50953796-3FAB8F82-106E-4ED7-927C-A3D15ADDF818Q50992637-2D3AE52C-20AD-4C74-8E50-C88FAF99716CQ52026719-E8E2BB4F-4F2E-43AC-812C-FFEEDD90C67DQ52643503-8D6715AF-EADF-4EAE-AC6B-3C1A3B436149Q53880896-9EE337CE-D046-43A5-B027-A263A1D900CBQ55006840-1C2D2962-B6BD-436C-8E14-5956052F1F00
P2860
Aberrant expression and reverse signalling of CD70 on malignant B cells.
description
1999 nî lūn-bûn
@nan
1999 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Aberrant expression and reverse signalling of CD70 on malignant B cells.
@ast
Aberrant expression and reverse signalling of CD70 on malignant B cells.
@en
type
label
Aberrant expression and reverse signalling of CD70 on malignant B cells.
@ast
Aberrant expression and reverse signalling of CD70 on malignant B cells.
@en
prefLabel
Aberrant expression and reverse signalling of CD70 on malignant B cells.
@ast
Aberrant expression and reverse signalling of CD70 on malignant B cells.
@en
P2093
P2860
P1476
Aberrant expression and reverse signalling of CD70 on malignant B cells.
@en
P2093
Drillenburg P
den Drijver BF
van Lier RA
van Oers MH
van Schijndel G
P2860
P304
P356
10.1046/J.1365-2141.1999.01573.X
P407
P577
1999-08-01T00:00:00Z